Shrestha Ananta
Department of Hepatology, Liver Foundation Nepal, Kathmandu, Nepal.
Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):63-65. doi: 10.5005/jp-journals-10018-1261. Epub 2018 May 1.
Hepatocellular carcinoma (HCC) is highly incidental in South Asian countries. Nepal, however, has low incidence for HCC owing to low prevalence for hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Nepal lacked national cancer registry until 2003. Though there has been some effort in having one, the current registry incorporates twelve centers and may not properly represent the total cancer burden in the country. Serology for HBV and HCV is seen to be positive in nearly 25 to 30% and 5 to 10% of HCCs respectively. Clinical characteristics of HCCs in Nepal have been discussed in this mini-review and it features poor performance status and advanced stage at presentation, making only a small fraction of these subjects eligible for curative treatment options. Most of the standard treatment modalities are available in Nepal and appear to be reasonably affordable as compared with other developed nations. Shrestha A. Liver Cancer in Nepal. Euroasian J Hepato-Gastroenterol 2018;8(1):63-65.
肝细胞癌（HCC）在南亚国家的发病率很高。然而，尼泊尔由于乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）感染率较低，HCC发病率也较低。直到2003年，尼泊尔都没有国家癌症登记处。尽管已经做出了一些努力来建立一个登记处，但目前的登记处包含12个中心，可能无法准确反映该国的总体癌症负担。在HCC患者中，HBV和HCV血清学检测呈阳性的比例分别约为25%至30%和5%至10%。本综述讨论了尼泊尔HCC的临床特征，其特点是临床表现较差且就诊时处于晚期，只有一小部分患者适合进行根治性治疗。尼泊尔可以获得大多数标准治疗方式，与其他发达国家相比，这些治疗方式似乎价格合理。什雷斯塔A. 尼泊尔的肝癌。《欧亚肝脏胃肠病学杂志》2018年；8(1):63 - 65。
